Flot.bio x Philip Hemme Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39
12 snips
Sep 24, 2025 
Alex Zhavoronkov, CEO of Insilico Medicine, discusses the game-changing role of AI in drug discovery and its potential impact on longevity. He shares insights into Insilico's impressive pipeline and the challenges faced by longevity startups. Alex emphasizes the importance of developing demonstrable benchmarks and the shift towards creating in-house assets. With a bold vision for manipulating aging, he advocates for increased investments in this field to drive innovation and breakthroughs.
AI Snips
Chapters
Transcript
Episode notes
A Conference Proposal
- Alex proposed to his fiancée at an aging conference after meeting her there through shared work.
- They now co-engage in longevity research and celebrated their engagement at the Copenhagen aging conference.
The Longevity Graveyard
- Many longevity startups failed clinically despite large funding rounds, creating a 'graveyard' of projects.
- Failures stem from scientific and non-scientific causes like cash runs and shifting founder focus.
Clinical Data Trumps AI Hype
- Clinical data ultimately validates AI drug discovery more than algorithms or demos.
- Owning and progressing your own assets captures far more value than licensing only the AI.